Medha Airy1, Jesse D Schold2,3, Stacey E Jolly4, Susana Arrigain5, Nisha Bansal6, Wolfgang C Winkelmayer1, Joseph V Nally2, Sankar D Navaneethan1,7. 1. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. 2. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. 3. Center for Populations Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. 4. Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. 5. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA. 6. Kidney Research Institute, University of Washington, Seattle, Washington, USA. 7. Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Abstract
BACKGROUND: Atrial fibrillation (AF) is associated with death in patients with chronic kidney disease (CKD). We examined the associations between AF and cause-specific mortality in a large CKD population. METHODS: We included 62,459 patients with estimated glomerular filtration rate 15-59 mL/min/1.73 m2 (6,639 patients with AF and 55,820 without AF) followed in a large health care system. Outcomes included overall and cause-specific deaths (a) cardiovascular; (b) malignancy; and (c) non-cardiovascular/non-malignancy causes. Cox regression models for overall mortality and separate competing risk models for each major cause of death category were used to evaluate their respective associations with AF. RESULTS: During a median follow-up of 4.1 years, 19,094 patients died; cause of death was known for 18,854 patients. After multivariable adjustment (demographics, comorbidities, relevant laboratory data, medication use, and kidney function), AF was associated with 23% (95% CI 18-29%) higher risk of all-cause mortality, 45% (95% CI 31-61%) higher risk of cardiovascular mortality and 13% (95% CI 3-22%) lower risk of malignancy-related mortality. Exclusion of patients with malignancy yielded similar results except for a lack of association between AF and malignancy-related deaths. Results were consistent across various stages of CKD. CONCLUSIONS: In a non-dialysis-dependent CKD population, the presence of AF was associated with higher all-cause and cardiovascular mortality. These data suggest that patients with both CKD and AF are at high cardiovascular risk, and thus clinical practice (or trials) should aim at reducing the overall excess cardiovascular mortality (not stroke alone) in patients with AF and CKD.
BACKGROUND:Atrial fibrillation (AF) is associated with death in patients with chronic kidney disease (CKD). We examined the associations between AF and cause-specific mortality in a large CKD population. METHODS: We included 62,459 patients with estimated glomerular filtration rate 15-59 mL/min/1.73 m2 (6,639 patients with AF and 55,820 without AF) followed in a large health care system. Outcomes included overall and cause-specific deaths (a) cardiovascular; (b) malignancy; and (c) non-cardiovascular/non-malignancy causes. Cox regression models for overall mortality and separate competing risk models for each major cause of death category were used to evaluate their respective associations with AF. RESULTS: During a median follow-up of 4.1 years, 19,094 patients died; cause of death was known for 18,854 patients. After multivariable adjustment (demographics, comorbidities, relevant laboratory data, medication use, and kidney function), AF was associated with 23% (95% CI 18-29%) higher risk of all-cause mortality, 45% (95% CI 31-61%) higher risk of cardiovascular mortality and 13% (95% CI 3-22%) lower risk of malignancy-related mortality. Exclusion of patients with malignancy yielded similar results except for a lack of association between AF and malignancy-related deaths. Results were consistent across various stages of CKD. CONCLUSIONS: In a non-dialysis-dependent CKD population, the presence of AF was associated with higher all-cause and cardiovascular mortality. These data suggest that patients with both CKD and AF are at high cardiovascular risk, and thus clinical practice (or trials) should aim at reducing the overall excess cardiovascular mortality (not stroke alone) in patients with AF and CKD.
Authors: Sankar D Navaneethan; Jesse D Schold; Stacey E Jolly; Susana Arrigain; Wolfgang C Winkelmayer; Joseph V Nally Journal: Am J Kidney Dis Date: 2017-02-10 Impact factor: 8.860
Authors: Marco V Perez; Paul J Wang; Joseph C Larson; Beth A Virnig; Barbara Cochrane; J David Curb; Liviu Klein; JoAnn E Manson; Lisa W Martin; Jennifer Robinson; Sylvia Wassertheil-Smoller; Marcia L Stefanick Journal: Circ Arrhythm Electrophysiol Date: 2012-11-20
Authors: James B Wetmore; Edward F Ellerbeck; Jonathan D Mahnken; Milind Phadnis; Sally K Rigler; Purna Mukhopadhyay; John A Spertus; Xinhua Zhou; Qingjiang Hou; Theresa I Shireman Journal: Ann Epidemiol Date: 2013-01-16 Impact factor: 3.797
Authors: Ditte-Marie Bretler; Peter Riis Hansen; Jesper Lindhardsen; Ole Ahlehoff; Charlotte Andersson; Thomas Bo Jensen; Jakob Raunsø; Christian Torp-Pedersen; Gunnar Hilmar Gislason Journal: PLoS One Date: 2012-12-17 Impact factor: 3.240
Authors: Tara I-Hsin Chang; Sai Liu; Medha Airy; Jingbo Niu; Mintu P Turakhia; Jennifer E Flythe; Maria E Montez-Rath; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2019-06-07 Impact factor: 8.237
Authors: Katherine Mikovna Scovner; Simon Correa; Brian L Claggett; Conor D Barrett; Sushrut S Waikar; Scott D Solomon; Finnian R Mc Causland Journal: Am J Nephrol Date: 2021-05-05 Impact factor: 3.754
Authors: Jennifer E Flythe; Sai Liu; Maria E Montez-Rath; Wolfgang C Winkelmayer; Tara I Chang Journal: Nephrol Dial Transplant Date: 2021-11-09 Impact factor: 7.186